<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164264">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959569</url>
  </required_header>
  <id_info>
    <org_study_id>GO/URC/ER/mm 459/DG</org_study_id>
    <nct_id>NCT00959569</nct_id>
  </id_info>
  <brief_title>Esmolol in Cardiac Surgery</brief_title>
  <acronym>BREVI</acronym>
  <official_title>Esmolol in Cardiac Surgery. A Randomized Controlled Trial With Clinical</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Vita-Salute San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università Vita-Salute San Raffaele</source>
  <brief_summary>
    <textblock>
      This large randomized double-blind clinical trial (esmolol vs placebo) will enroll patients
      undergoing cardiac surgery to study the additive cardiac protection of this therapeutic
      strategy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint or number of dead patients and/or number of patients requiring prolonged ICU stay.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with ventricular fibrillation after cardiopulmonary bypass</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with low cardiac output syndrome</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring post-operative inotropic support</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak postoperative cardiac troponin level</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the study group will receive esmolol (1-3 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normosaline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normosaline (same ml of the study drug)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>esmolol (1-3 mg/kg) during cardiac surgery</description>
    <arm_group_label>esmolol</arm_group_label>
    <other_name>Beta-blocker; Beta blocker; breviblock</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normosaline (same ml of the study drug)</description>
    <arm_group_label>normosaline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  end diastolic diameter &gt;60 mm and an ejection fraction &lt;50%

          -  written informed consent

          -  age &gt;18 years

        Exclusion Criteria:

          -  previous unusual response to esmolol

          -  inclusion in other randomized studies

          -  esmolol administration in the previous 30 days

          -  emergency operation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>giovanni landoni, MD</last_name>
    <email>landoni.giovanni@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>elena bignami, MD</last_name>
    <email>bignami.elena@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vita-Salute University</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>giovanni landoni, MD</last_name>
      <email>landoni.giovanni@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>elena bignami, MD</last_name>
      <email>bignami.elena@hsr.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Zangrillo A, Turi S, Crescenzi G, Oriani A, Distaso F, Monaco F, Bignami E, Landoni G. Esmolol reduces perioperative ischemia in cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth. 2009 Oct;23(5):625-32. doi: 10.1053/j.jvca.2009.01.003. Epub 2009 Mar 18.</citation>
    <PMID>19297196</PMID>
  </reference>
  <reference>
    <citation>Crescenzi G, Rosica C, Marino G, Serini SM, Covello RD, Landoni G, Zangrillo A. The use of esmolol to treat systolic anterior motion of the mitral valve after mitral valve repair. Eur J Anaesthesiol. 2008 Apr;25(4):342-3. doi: 10.1017/S0265021507002876.</citation>
    <PMID>18334040</PMID>
  </reference>
  <reference>
    <citation>Landoni G, Zambon M, Zangrillo A. Reducing perioperative myocardial infarction with anesthetic drugs and techniques. Curr Drug Targets. 2009 Sep;10(9):858-62. Epub 2009 Sep 1. Review.</citation>
    <PMID>19538174</PMID>
  </reference>
  <reference>
    <citation>Crescenzi G, Landoni G, Zangrillo A, Guarracino F, Rosica C, La Canna G, Alfieri O. Management and decision-making strategy for systolic anterior motion after mitral valve repair. J Thorac Cardiovasc Surg. 2009 Feb;137(2):320-5. doi: 10.1016/j.jtcvs.2008.08.018.</citation>
    <PMID>19185145</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 20, 2015</lastchanged_date>
  <firstreceived_date>August 13, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Landoni Giovanni</name_title>
    <organization>Vita-Salute University of Milano, Italy</organization>
  </responsible_party>
  <keyword>esmolol</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>cardiac anesthesia</keyword>
  <keyword>mortality</keyword>
  <keyword>beta blockers</keyword>
  <keyword>beta-blockers</keyword>
  <keyword>cardiac protection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
